Program

Join our sponsors for industry symposiums

Friday, February 2, 2024 - Saanich Room

12:30pm - 1:30pm Merck Symposium + Lunch

The Changing Landscape of HPV How to Protect Your Patients
Speaker: Dr. Angel Chu

Learning Objectives:

  • Outline the burden of HPV related disease and cancers in Canada

  • Discuss the latest clinical data and recommendations for HPV immunization

  • Discuss current immunization recommendations (National Advisory Committee on Immunization) and schedules

  • Describe opportunities to initiate discussions and counsel about HPV and HPV prevention

5:15pm - 6:15pm Sanofi Symposium + Reception

Is the Elephant in the Room? Tackling the unmet RSV disease burden in British Columbia’s pediatric population.
Speaker: Dr. Jennifer Balfour and Dr. Nirma Khatri Vadlamudi

Learning Objectives:

  • Review the impact of RSV disease in pediatric populations in British Columbia and lessons learned from a front-line clinician's perspective.

  • Appreciate current pediatric RSV disease epidemiology in BC and challenges surrounding the current Immunoprophylaxis program.

  • Explore solutions to address the persisting disease burden.  

Saturday, February 3, 2024 - Saanich Room

7:15am - 8:15am Pfizer Symposium + Breakfast

New Respiratory Syncytial Virus (RSV) Vaccines: Lets Protect Infants and Older Adults
Speaker: Dr. George G. Zhanel

Learning Objectives:

  • Describe the need for respiratory syncytial virus (RSV) infection prevention in children and older adults

  • Discuss the clinical presentation, diagnosis, testing, and current standard of care for RSV infection

  • Review the new RSV vaccines available or in development in Canada

  • Discuss case studies of patients who should be considered for RSV vaccination

12:15pm - 1:15pm Paladin Symposium + Lunch

Management of Moderate to Severe MRSA Infection in Difficult to Engage Patients
Speaker: Dr. Daniel Smyth

Learning Objectives:

  • Explore the challenges of treating moderate to severe MRSA infection in difficult-to-engage patients

  • Review the pharmacology, indications, and advantages/disadvantages of oral and parenteral MRSA treatment options  

  • Review strategies to facilitate discharge in the context of an overwhelmed healthcare system, including shorter course therapies, early IV to PO transition, and longer acting parenteral options